GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

vanucizumab   Click here for help

GtoPdb Ligand ID: 9132

Synonyms: RG-7221 | RG7221 | RO5520985
Compound class: Antibody
Comment: Vanucizumab is an investigational bi-specific monoclonal antibody, with potential anti-neoplastic activity being developed by Hoffmann-La Roche [1-2]. Vanucizumab simultaneously targets angiopoietin 2 (ANGPT2) and vascular endothelial growth factor A (VEGFA).
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. BLAST seuqence analysis reveals 100% matches with peptide sequences claimed in patent US8945552 and likely identify XMab1 and XMab2 as candidates for vanucizumab [1].
Bioactivity Comments
XMab1 in [1] was used to produce binding affinity data.
Selectivity at ligand targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
VEGFA Primary target of this compound Hs Antibody Binding >10.0 pKd - 1
⤷ pKd >10.0 (Kd <1x10-10 M) [1]
angiopoietin-2 Primary target of this compound Hs Antibody Binding 9.6 pKd - 1
⤷ pKd 9.6 (Kd 2.4x10-10 M) [1]